Our latest articles
Tuck-ins are the order of the day, although new chief doesn’t rule out a large buy.
Momelotinib, a Jak inhibitor that has been through four companies, yields a positive result in its pivotal Momentum trial.
But further data do not shed much light on Onpattro’s chances in Apollo-B.
The agency takes its time – particularly with diagnostics.
Astrazeneca looks to enter a field in which Merck & Co recently tripped up, and in which Roche is the only IO player.
Medtechs rushed for the markets last year, but had an uneasy time once there.
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
How long can it be before the total breaches $10bn?